# Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)

> **NCT01019486** · PHASE4 · COMPLETED · sponsor: **University of Colorado, Denver** · enrollment: 26 (actual)

## Conditions studied

- Coronary Artery Disease
- Type 1 Diabetes Mellitus

## Interventions

- **DRUG:** Regadenoson myocardial perfusion imaging
- **DRUG:** Regadenoson MRI myocardial blood flow

## Key facts

- **NCT ID:** NCT01019486
- **Lead sponsor:** University of Colorado, Denver
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2011-12
- **Final completion:** 2011-12
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2015-12-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01019486

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01019486, "Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01019486. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*